| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000027835 |
| Receipt No. | R000031871 |
| Official scientific title of the study | Comparison of weight loss effect of diabetes treatment for obese type 2 diabetic patients. |
| Date of disclosure of the study information | 2017/06/26 |
| Last modified on | 2017/06/20 (Ver. 1) |
| Basic information | ||
| Official scientific title of the study | Comparison of weight loss effect of diabetes treatment for obese type 2 diabetic patients. | |
| Title of the study (Brief title) | Comparison of weight loss effect of diabetes treatment for obese type 2 diabetic patients. | |
| Region |
|
|
| Condition | ||
| Condition | Diabetes | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | By bariatric surgery on obese type 2 diabetic patients, not only weight loss effect but also metabolic improvement effect can be expected. However, bariatric surgery, which is applied for insurance in Japan, is only sleeve gastrectomy. Patients with obesity, which is an indication for surgery, are, in principle, patients with primary obesity between the ages of 18 and 65, and there is no significant weight loss and no improvement in obesity related complications despite medical treatments for more than 6 months.
Until recently, although diabetes treatment have an effect of improving blood glucose, body weight gain accompanying treatment became a problem. GLP-1 receptor agonist and SGLT2 inhibitor are on the market. I evaluated the effect of GLP-1 receptor agonist and SGLT-2 inhibitor on obese type 2 diabetic patients on the parameters of blood glucose and BMI. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | HbA1c(0M,6M) |
| Key secondary outcomes | BMI(0M,6M) |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Active |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 3 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | The group treated with GLP-1 receptor agonist(Duration:6 months) | |
| Interventions/Control_2 | The group treated with SGLT-2 inhibitor(Duration:6 months) | |
| Interventions/Control_3 | The group treated with GLP-1 receptor agonist and SGLT-2 inhibitor(Duration:6 months) | |
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | BMI>=22.0 | |||
| Key exclusion criteria | Renal dysfunction(eGFR>=30mL/min/1.73m2) | |||
| Target sample size | 60 | |||
| Research contact person | |
| Name of lead principal investigator | Takahisa Hasegawa |
| Organization | KYORITSU HOSPITAL |
| Division name | internal medicine |
| Address | 16-5, Chuo-cho, Kawanishi-city,Hyogo |
| TEL | 072-758-1131 |
| h.taka517@gmail.com | |
| Public contact | |
| Name of contact person | Takahisa Hasegawa |
| Organization | KYORITSU HOSPITAL |
| Division name | internal medicine |
| Address | 16-5, Chuo-cho, Kawanishi-city,Hyogo |
| TEL | 072-758-1131 |
| Homepage URL | |
| h.taka517@gmail.com | |
| Sponsor | |
| Institute | KYORITSU HOSPITAL |
| Institute | |
| Department | |
| Funding Source | |
| Organization | KYORITSU HOSPITAL |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 協立病院 |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031871 |